Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Post-GPI attachment to proteins factor 6 (PGAP6) is a transmembrane phospholipase A2 enzyme involved in post-translational lipid remodeling of glycosylphosphatidylinositol (GPI) anchors. It specifically removes a fatty acyl-chain at the sn-2 position of the GPI anchor, which is essential for the maturation and function of a subset of GPI-anchored proteins. PGAP6 has a large extracellular N-terminal domain and seven transmembrane domains, and belongs to the CREST superfamily of lipases. Its enzymatic activity is highly specific, targeting only a limited set of GPI-anchored proteins, notably triggering the release (shedding) of CRIPTO, a GPI-anchored co-receptor critical for Nodal signaling in embryonic development. By enabling the release of soluble CRIPTO, PGAP6 finely regulates intercellular signaling events, particularly in early embryogenesis. Pathogenic variants in PGAP6 have been associated with neurological and developmental disorders, and dysfunction in GPI-anchor processing can broadly affect cell signaling and development[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Post-GPI attachment to proteins factor 6 (PGAP6).